Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Glycitin is an isoflavone glycoside found predominantly in soybeans. Its use in supporting or treating osteoporosis is supported by some scientific evidence, mostly from preclinical and animal studies, but evidence in humans remains limited, which is why the evidence rating is 2 out of 5. Isoflavones, including glycitin, are known to have phytoestrogenic effects, meaning they can mimic estrogen in the body to some extent. Since estrogen deficiency is a key factor in postmenopausal osteoporosis, compounds with estrogen-like activity have been investigated for their potential to prevent bone loss.

Several in vitro and animal studies have shown that glycitin and its aglycone, glycitein, can promote osteoblast differentiation and inhibit osteoclast activity, both of which are beneficial for bone health. For example, some studies suggest that glycitin may activate the Wnt/β-catenin signaling pathway, which is involved in bone formation, and decrease markers of bone resorption. Glycitin has also been shown to exhibit antioxidative properties, potentially reducing oxidative stress-induced bone loss.

However, human clinical trials directly evaluating glycitin for osteoporosis are sparse. Much of the human data on isoflavones and bone health comes from studies using mixtures of soy isoflavones (genistein, daidzein, and glycitin), making it difficult to isolate the effects of glycitin alone. Therefore, while there is a scientific rationale and some preclinical support, strong clinical evidence for glycitin’s efficacy in osteoporosis is lacking.

More about glycitin
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by glycitin

Products containing glycitin

Metagenics Testralin®